A detailed history of Polar Capital Holdings PLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Polar Capital Holdings PLC holds 1,500,000 shares of RYTM stock, worth $84.2 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
1,500,000
Previous 1,500,000 -0.0%
Holding current value
$84.2 Million
Previous $61.6 Million 27.59%
% of portfolio
0.48%
Previous 0.38%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$39.12 - $52.44 $9.78 Million - $13.1 Million
-250,000 Reduced 14.29%
1,500,000 $65 Million
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $16 Million - $37.2 Million
-750,000 Reduced 30.0%
1,750,000 $80.4 Million
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $3.95 Million - $6.95 Million
250,000 Added 11.11%
2,500,000 $57.3 Million
Q2 2023

Dec 13, 2023

BUY
$16.32 - $21.15 $8.16 Million - $10.6 Million
500,000 Added 28.57%
2,250,000 $37.1 Million
Q2 2023

Aug 14, 2023

BUY
$16.32 - $21.15 $8.16 Million - $10.6 Million
500,000 Added 28.57%
2,250,000 $37.1 Million
Q1 2023

Dec 13, 2023

SELL
$16.88 - $34.24 $12.7 Million - $25.7 Million
-750,000 Reduced 30.0%
1,750,000 $31.2 Million
Q1 2023

May 15, 2023

BUY
$16.88 - $34.24 $8.44 Million - $17.1 Million
500,000 Added 40.0%
1,750,000 $31.2 Million
Q4 2022

Feb 14, 2023

BUY
$22.21 - $30.25 $11.9 Million - $16.2 Million
535,261 Added 74.89%
1,250,000 $36.4 Million
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $3.07 Million - $22 Million
714,739 New
714,739 $17.5 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.13B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.